MOTS-c Legal Status, FDA 503A Category, and Compounding Access

The gist

Here is the MOTS-c legal status in plain words, lead first: the picture is in motion. The FDA has put MOTS-c on the agenda of a public advisory-committee meeting on July 23–24, 2026, where it is named as a substance "being considered for inclusion" on the list that governs pharmacy compounding ^[18]. That is real momentum — and it is also just a meeting on the calendar, not a ruling. Today, MOTS-c is a research chemical: not an FDA-approved medicine, not a dietary supplement, sold only for laboratory use. This page explains the rules that decide compounded access and shows exactly where MOTS-c sits inside them right now.

The Current Status of MOTS-c, Stated as Fact

MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is not an FDA-approved drug for any indication. It is sold only for laboratory research, with no approved human indication, formulation, or dosing.

Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list ^[16]. Substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC) ^[16].

MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation ^[18]. Being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding. This page does not assign MOTS-c a numbered 503A category: the audited FDA record places MOTS-c on a meeting agenda for evaluation, and its present-tense status is precisely that — a research peptide scheduled for PCAC discussion ^[18].

Individually Named on the July 2026 FDA Advisory-Committee Agenda

The forward-leaning fact, stated carefully: MOTS-c is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" ^[18]. FDA's calendar lists it for evaluation in both its free-base and acetate forms, and the same agenda also names BPC-157, TB-500, and KPV ^[18].

What that means — and does not mean — is the whole point. A scheduled PCAC discussion is a step in FDA's evaluation, not a final listing decision ^[16]. The committee is advisory: it discusses, and FDA decides separately through rulemaking ^[16]. So this is a scheduled evaluation only — not a listing, not a reclassification, and not a change in MOTS-c's current status ^[18]. No outcome of the meeting can be assumed, stated, or dated. The momentum is genuine; the decision is not yet made.

The 503A and 503B Compounding Framework

Two sections of federal law govern drug compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient ^[16]. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection ^[16].

The pivotal rule is about ingredients. A compounder may use a bulk drug substance — an active pharmaceutical ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[16][17]. Substances not yet on a bulks list are evaluated through FDA's public nomination process with PCAC input ^[16]. FDA's separate approval of a finished drug is a different question from whether a bulk substance may be used in compounding; MOTS-c is neither an approved drug nor on the final bulks list today ^[16][18]. A substance that FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[17].

How Legally Compounded Peptide Access Works

In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription ^[19]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[19].

The sequence runs: a licensed-prescriber evaluation — which may begin through telehealth as a front-end consultation channel — leads to a valid prescription, which is filled by a 503A pharmacy or sourced from a 503B facility ^[19]. Telehealth is simply a route to that prescriber evaluation; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription ^[19]. The ingredient-eligibility caveat is the gate that matters: the compounder may use the requested ingredient only if it is eligible under the 503A/503B rules, and an ingredient FDA has identified as raising significant safety risks is not eligible for routine 503A compounding while that status holds ^[19]. This is general information about the regulatory landscape — not medical or legal advice, and not an offer to sell or supply any substance.

Anti-Doping Status in Sport

Separately from the FDA framework, MOTS-c is treated as a prohibited substance in elite sport. Anti-doping authorities such as USADA and WADA classify it among peptide and metabolic-modulator agents prohibited at all times, and athlete use can result in sanctions. This is an anti-doping classification governing competition — distinct from the FDA compounding question above — and it is one more reason the access picture for MOTS-c is narrow rather than open today. The research that drives interest in the compound is summarized on the MOTS-c benefits reported in the literature page.